Allergy Therapeutics PLC Hardman Research: Performance drives market share
September 26 2016 - 5:46AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
26 September 2016
Hardman Research: Performance drives market share
Excellent performance drives market share gains: Allergy
Therapeutics is a long-established specialist in the prevention,
diagnosis and treatment of allergies. Pollinex Quattro continues to
gain market share despite being available in Europe only on a
'Named Patient' basis. Trials to obtain full regulatory approval as
a biological have progressed well in the EU, but the setback in the
US will delay market entry by approximately 12 months. Despite
this, AGY remains on course to have the first short-course allergy
vaccine approved in both Europe and the US. Despite an operational
performance significantly better than all of its competitors, AGY
still trades well below the ratings of its international peer
group.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/26.09.16-excellent-performance-drives-market-share-gains.pdf
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Dr Dorothea Hill
Yard dmh@hardmanandco.com
London Dr Gregoire Pave
EC2R 7AS gp@hardmanabdco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEANNKALAKEEF
(END) Dow Jones Newswires
September 26, 2016 05:46 ET (09:46 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024